ADC Therapeutics SA (NYSE: ADCT), a Swiss developer of antibody drug conjugates (ADCs), announced on Tuesday the completion of enrolment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

The trial involves 100 r/r DLBCL patients dosed at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab. Patients were enrolled at 30 sites with 70% in the United States and 30% in the EU. The study enrolled patients with baseline characteristics similar to other bispecific combination studies in this space and included 46% relapsed and 54% primary refractory patients with a median age of 66 years.

Primary endpoints of the study include safety and tolerability, with secondary endpoints including overall response rate, duration of response, complete response, relapse free survival, progression-free survival, and overall survival, as well as pharmacokinetics and immunogenicity. As part of the study protocol, anti-infective prophylaxis, intravenous immunoglobulin (in patients experiencing B-cell loss with an increased risk of infection) and vaccination are strongly recommended.

Further to the previously reported results from LOTIS-7 demonstrating promising clinical activity for the combination of ZYNLONTA plus glofitamab in patients with r/r DLBCL, ADC Therapeutics plans to share full data from LOTIS-7 at a medical meeting and submit the results for publication by the end of 2026.